Bausch + Lomb Corporation
Bausch + Lomb Corporation (BLCO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
blco · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bausch + Lomb Corporation (BLCO) measures how much investors pay for each dollar of the company's trailing earnings. BLCO's current PE ratio of N/A is calculated by dividing its stock price of $15.46 by its TTM earnings per share of -$0.62.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 4 fiscal years · Front-end computedMinQ1 · 25%31.0x
MedianQ3 · 75%904.7x
Max
At N/A, BLCO's current P/E is lower than in 0% of its annual fiscal year readings over the past 4 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bausch + Lomb CorporationYou BLCO | $5.5B | N/A | — | -$0.62 |
 Arcellx, Inc. ACLX | $6.7B | N/A | — | -$4.07 |
 Arrowhead Pharmaceuticals, Inc. ARWR | $10.3B | N/A | — | -$0.01 |
 CRISPR Therapeutics AG CRSP | $5.0B | N/A | — | -$6.47 |
 Glaukos Corporation GKOS | $7.3B | N/A | — | -$3.28 |
 Merit Medical Systems, Inc. MMSI | $3.8B | 40.58x | — | $2.17 |
 Oscar Health, Inc. OSCR | $6.4B | N/A | — | -$1.69 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.02 | — | |
2024-12-31 FY2024 | — | $-0.90 | — | |
2023-12-31 FY2023 | — | $-0.74 | — | |
2022-12-31 FY2022 | 904.75x | $0.02 | +2252.3% | |
2021-12-31 FY2021 | 38.46x | $0.52 | — | |
2020-12-31 FY2020 | — | $-0.05 | — | |
2019-12-31 FY2019 | 23.49x | $0.85 | +138.3% | |
2018-12-31 FY2018 | 9.86x | $2.03 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bausch + Lomb Corporation (BLCO) measures how much investors pay for each dollar of the company's trailing earnings. BLCO's current PE ratio of N/A is calculated by dividing its stock price of $15.46 by its TTM earnings per share of -$0.62.
Frequently asked questions
BLCO pe ratio · 6 questionsBLCO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $15.46 and TTM EPS of -$0.62. Data sourced from Financial Modeling Prep via BLCO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bausch + Lomb Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08